Recurrences of superficial bladder carcinoma are associated with a raise of CD8highCD57+ and CD8low T lymphocytes in peripheral blood

Open Cancer Immunology Journal

Volumn 3, Issue , 2010, Pages 8-14

  Jacobs, John J L ^a   Characiejus, Dainius ^b   Pašukoniene, Vita ^b   Jankevičius, Feliksas ^b   van Moorselaar, R Jeroen A ^a   Mauricas, Mykolas ^b   Den Otter, Willem ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VILNIUS UNIVERSITY   (Lithuania)

Author keywords

Antigen specific; Bladder carcinoma; CD57; CD8; Immune suppression; Interleukin 2; Recurrence free period

Indexed keywords

BCG VACCINE; CD57 ANTIGEN; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RECURRENCE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; SUPERFICIAL CANCER; TRANSURETHRAL RESECTION;

EID: 79953250828     PISSN: None     EISSN: 18764010     Source Type: Journal    
DOI: 10.2174/1876401001003010008     Document Type: Article

References (54)

1. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54: 303-14.
2. Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 2007; 52: 1123-29.
3. Witjes JA, Hendricksen K. Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur Urol 2008; 53: 45-52.
4. Böhle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003; 170: 964-9.
5. Patard JJ, Saint F, Velotti F, Abbou CC, Chopin DK. Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review. Urol Res 1998; 26: 155-9.
6. Sharma P, Shen Y, Wen S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA 2007; 104: 3967-72.
7. Saint F, Salomon L, Quintela R, et al. Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin (BCG) immunotherapy exist? Analysis of a quarter century of literature. Eur Urol 2003; 43: 351-60.
8. De Reijke TM, De Boer EC, Kurth KH, Schamhart DH. Urinary cytokines during intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognosis value. J Urol 1996; 155: 477-82.
9. Saint F, Kurth N, Maille P, et al. Urinary IL-2 assay for monitoring intravesical Bacillus Calmette-Guérin response of superficial bladder cancer during induction course and maintenance therapy. Int J Cancer 2003; 107: 434-40.
10. Watanabe E, Matsuyama H, Matsuda K, et al. Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette- Guérin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother 2003; 52: 481-6.
11. Den Otter W, Jacobs JJL, Battermann JJ, et al. Local therapy of cancer with free IL-2. Cancer Immunol Immunother 2008; 57: 931-50.
12. Shaker MA, Younes HM. Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy. J Pharm Sci 2009; 98: 2268-98.
13. Jacobs JJL, Sparendam D, Den Otter W. Local interleukin 2 therapy is most effective against cancer when injected intratumourally. Cancer Immunol Immunother 2005; 54: 647-54.
14. Maas RA, Van Weering DHJ, Dullens HFJ, Den Otter W. Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour. Cancer Immunol Immunother 1991; 33: 389-94.
15. Spoormakers TJ, Klein WR, Jacobs JJL, Van Den Ingh TS, Koten JW, Den Otter W. Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or cisplatin/IL-2. Cancer Immunol Immunother 2003; 52: 179-84.
16. Stewart RJE, Masztalerz A, Jacobs JJL, Den Otter W. Local interleukin-2 and interleukin-12 therapy of bovine ocular squamous cell carcinomas. Vet Immunol Immunopathol 2005; 106: 277-84.
17. Jacobs JJL, Hordijk GJ, Jürgenliemk-Schulz IM, et al. Treatment of stage III-IV nasopharyngeal carcinomas by external beam irradiation and local low doses of IL-2. Cancer Immunol Immunother 2005; 54: 792-8.
18. Radny P, Caroli U, Bauer J, et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 2003; 89: 1620-6.
19. Vlad AM, Budiu RA, Lenzner DE, et al. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother 2010; 59: 293-301.
20. Pizza G, Severini G, Menniti D, De Vinci C, Corrado F. Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report. Int J Cancer 1984; 34: 359-67.
21. Huland E, Huland H. Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res 1989; 49: 5469-74.
22. Gomella LG, McGinnis DE, Lattime EC, et al. Treatment of transitional cell carcinoma of the bladder with intravesical interleukin-2: a pilot study. Cancer Biother 1993; 8: 223-7.
23. Den Otter W, Dobrowolski Z, Bugajski A, et al. Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients. J Urol 1998; 159: 1183-6.
24. Grasso M, Torelli F, Scannapieco G, Franzoso F, Lania C. Neoadiuvant treatment with intravesical interleukin-2 for recurrent superficial transitional bladder carcinoma Ta-T1/G1-2. J Immunother 2001; 24: 184-7.
25. Ferlazzo G, Magno C, Iemmo R, et al. Treatment of superficial bladder cancer with intravesical perfusion of rIL-2: a follow-up study. Anticancer Res 1996; 16: 979-80.
26. Ferlazzo G, Magno C, Lupo G, et al. A phase I study of intravesical continuous perfusion of recombinant interleukin-2 in patients with superficial bladder cancer. Am J Clin Oncol 1995; 18: 100-4.
27. Tubaro A, Stoppacciaro A, Velotti F, et al. Local immunotherapy of superficial bladder cancer by intravesical instillation of recombinant interleukin-2. Eur Urol 1995; 28: 297-303.
28. Autran B, Leblond V, Sadat-Sowti B, et al. A soluble factor released by CD8+CD57+ lymphocytes from bone marrow transplanted patients inhibits cell-mediated cytolysis. Blood 1991; 77:2237-41.
29. Frassanito MA, Silvestris F, Cafforio P, Dammacco F. CD8+/CD57+ cells and apoptosis suppress T-cell functions in multiple myeloma. Br J Haematol 1998; 100: 469-77.
30. Chochi K, Ichikura T, Majima T, et al. The increase of CD57+ T cells in the peripheral blood and their impaired immune functions in patients with advanced gastric cancer. Oncol Rep 2003; 10:1443-8.
31. Mollet L, Sadat-Sowti B, Duntze J, et al. CD8hi+CD57+ T lymphocytes are enriched in antigen-specific T cells capable of downmodulating cytotoxic activity. Int Immunol 1998; 10: 311-23.
32. Wang EC, Lehner PJ, Graham S, Borysiewicz LK. CD8high (CD57+) T cells in normal, healthy individuals specifically suppress the generation of cytotoxic T lymphocytes to Epstein-Barr virus-transformed B cell lines. Eur J Immunol 1994; 24: 2903-9.
33. Kienzle N, Baz A, Kelso A. Profiling the CD8low phenotype, an alternative career choice for CD8 T cells during primary differentiation. Immunol Cell Biol 2004; 82: 75-83.
34. Naji A, Le Rond S, Durrbach A, et al. CD3+CD4low and CD3+CD8low are induced by HLA-G: novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance. Blood 2007; 110: 3936-48.
35. Characiejus D, Pasukoniene V, Kazlauskaite N, et al. Predictive value of CD8highCD57+ lymphocyte subset in interferon therapy of patients with renal cell carcinoma. Anticancer Res 2002; 22:3679-83.
36. Mackay CR, Kimpton WG, Brandon MR, Cahill RN. Lymphocyte subsets show marked differences in their distribution between blood and the afferent and efferent lymph of peripheral lymph nodes. J Exp Med 1988; 167: 1755-65.
37. Di Girolamo W, Coronato S, Portiansky E, Laguens G. Profile of immune cells in lymph nodes draining human malignant tumors. Medicina (B Aires) 2008; 68: 423-7.
38. Reyes E, Carballido J, Manzano L, Moltó L, Olivier C, Alvarez-Mon M. The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients. Br J Cancer 1999; 79: 1162-7.
39. Shaw M, Ray P, Rubenstein M, Guinan P. Lymphocyte subsets in urologic cancer patients. Urol Res 1987; 15: 181-5.
40. Agarwal A, Verma S, Burra U, Murthy NS, Mohanty NK, Saxena S. Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder. Cancer Immunol Immunother 2006; 55: 734-43.
41. Ibs KH, Rink L. The immune system in aging. Z Gerontol Geriatr 2001; 34: 480-5.
42. Panda A, Arjonal A, Sapey E, et al. Human innate immunosenes-cence: causes and consequences for immunity in old age. Trends Immunol 2009; 30: 325-33.
43. Blish CA, Dillon SR, Farr AG, Fink PJ. Anergic CD8+ T cells can persist and function in vivo. J Immunol 1999; 193: 155-64.
44. Kienzle N, Olver S, Buttigieg K, et al. Progressive differentiation and commitment of CD8+ T cells to a poorly cytolytic CD8low phenotype in the presence of IL-4. J Immunol 2005; 174: 2021-9.
45. Brenchley JM, Karandikar NJ, Betts MR, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 2003; 101: 2711-20.
46. Ohkawa T, Seki S, Dobashi H, et al. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells. Immunology 2001; 103: 281-90.
47. Mathé G, Morette C, Hallard M, Sala M, Orbach-Arbouys S. Changes in the level of blood suppressor CD8+CD57+ lymphocytes, when HIV-1 p24 antigen reappears in the blood. Biomed Pharmacother 1994; 48: 3-5.
48. Mueller TF. Phenotypic changes with immunosuppression in human recipients. Front Biosci 2003; 8: 1254-74.
49. Billerbeck E, Nakamoto N, Seigel B, Blum H, Chang K, Thimme R. Determinants of in vitro expansion of different human virus-specific FoxP3+ regulatory CD8+ T cells in chronic hepatitis C virus infection. J Gen Virol 2009; 90: 1692-701.
50. Wood KL, Twigg HLr, Doseff AI. Dysregulation of CD8+ lymphocyte apoptosis, chronic disease, and immune regulation. Front Biosci 2009; 14: 3771-81.
51. Magno C, Melloni D, Galì A, et al. The anti-tumor activity of bacillus Calmette-Guerin in bladder cancer is associated with an increase in the circulating level of interleukin-2. Immunol Lett 2002; 81: 235-8.
52. Characiejus D, Pasukoniene V, Jonusauskaite R, et al. Periphera blood CD8highCD57+ lymphocyte levels may predict outcome in melanoma patients treated with adjuvant interferon-alpha. Anticancer Res 2008; 28: 1139-42.
53. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006;108: 804-11.
54. Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol 2008; 20: 241-6.